The Impact of Glucocorticoid Treatment on Tfh Cell in Myasthenia Gravis Patients
Zhao Xu;Haicheng Central Hospital, department of internal neurology;
Objective To explore the potential effects of glucocorticoid treatment on Tfh cell population in myasthenia gravis patients. Methods30 patients newly diagnosed with myasthenia gravis and treated in our hospital as well as 20 healthy controls from Oct 2015 to Sep 2016 were given oral glucocorticoid treatment. Changes of CXCR5, ICOS and transcriptional factor Bcl-6 were determined by flow cytometry. Serum IL-21 was measured by ELISA. Results(1)Compared with healthy controls, the percentage of Tfh cells were significantly elevated and decreased after glucocorticoid treatment;(2)The expression of ICOS and Bcl-6 was significantly higher in MG patients compared with healthy controls, however, only the level of ICOS was significantly down-regulated after glucocorticoid therapy;(3)Serum IL-21 was significantly higher in MG patients compared with control littermates and glucocorticoid treatment could obviously returns to normal level. Conclusion(1)The imbalance of Tfh cells may take part in the pathogenesis of MG occurrence and correlated with clinical therapeutic outcome;(2) Glucocorticoid treatment may inhibit autoantibody production through inhibiting the secretion of IL-21 by Tfh cells.
【CateGory Index】： R746.1